⌕
Biomarin Pharmaceutical · BMRN · Nasdaq
Tenet 43 · Weak
Compare
$58.51+0.90%At closeTenet 43 · Weak
$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Biomarin Pharmaceutical (BMRN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is BMRN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 10:32 ET
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

BMRN +0.9% todayRead at source ↗
● MarketBeatNov 16, 2026 · 08:12 ET
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms

BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hard…

BMRN +0.9% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 07:12 ET
BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript…

BMRN +0.9% todayRead at source ↗
● MarketBeatNov 11, 2026 · 20:13 ET
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline

BioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion.…

BMRN +0.9% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 19:48 ET
BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript…

BMRN +0.9% todayRead at source ↗
● Defense WorldNov 6, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 23
Bfsg LLC Buys 17,538 Shares of BioMarin Pharmaceutical Inc. $BMRN

Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,538 shares of the bio…

BMRN +0.9% todayRead at source ↗
● Defense WorldNov 5, 2026 · 01:21 ET
Traders Buy Large Volume of BioMarin Pharmaceutical Call Options (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an increase of approximately …

BMRN +0.9% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 11:33 ET
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions

BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, an…

BMRN +0.9% todayRead at source ↗
● PRNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
BioMarin to Participate in Upcoming Investor Conferences

Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /P…

BMRN +0.9% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 00:58 ETEARNINGS EXPECTED BY FEB 23
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript

BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive V…

BMRN +0.9% todayRead at source ↗
● MarketBeatNov 2, 2026 · 21:15 ETEARNINGS EXPECTED BY FEB 23
BioMarin Pharmaceutical Q3 Earnings Call Highlights

BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. Th…

BMRN +0.9% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 19:01 ETEARNINGS EXPECTED BY FEB 23
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-…

BMRN +0.9% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 18:56 ETEARNINGS EXPECTED BY FEB 23
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a year ago.…

BMRN +0.9% todayRead at source ↗
● PRNewsWireNov 2, 2026 · 16:03 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
BioMarin Reports Third Quarter 2026 Financial and Operating Results

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Ord…

BMRN +0.9% todayRead at source ↗
● Defense WorldOct 31, 2026 · 04:03 ET
BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $58.44 and traded as high as $59.37.…

BMRN +0.9% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 08:45 ETCOMPANY'S OWN WORDS
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront payment of $70 milli…

BMRN +0.9% todayRead at source ↗
● PRNewsWireOct 26, 2026 · 09:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webca…

BMRN +0.9% todayRead at source ↗
● Defense WorldOct 26, 2026 · 05:05 ETEARNINGS EXPECTED BY FEB 23
Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN

Quadrant Capital Group LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during a recent quarter, according to its most recent filing with the SEC. The fund bought 9,402 shares of the biotec…

BMRN +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 19, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 23
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

BMRN +0.9% todayRead at source ↗
● Defense WorldOct 17, 2026 · 03:49 ETEARNINGS EXPECTED BY FEB 23
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position

Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securi…

BMRN +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 13, 2026 · 10:41 ET
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

BMRN +0.9% todayRead at source ↗
● Defense WorldOct 12, 2026 · 01:59 ETEARNINGS EXPECTED BY FEB 23
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)

Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on…

BMRN +0.9% todayRead at source ↗
● PRNewsWireOct 9, 2026 · 09:05 ETCOMPANY'S OWN WORDS
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pha…

BMRN +0.9% todayRead at source ↗
● PRNewsWireOct 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
BioMarin Appoints Cara Bauer as Chief People Officer

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceut…

BMRN +0.9% todayRead at source ↗
● PRNewsWireOct 2, 2026 · 11:00 ETCOMPANY'S OWN WORDS
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new dat…

BMRN +0.9% todayRead at source ↗
● Business WireSep 30, 2026 · 07:00 ET
Profluent Partners With BioMarin to Design Novel Medicines Using AI

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BMRN--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pi…

BMRN +0.9% todayRead at source ↗
● PRNewsWireSep 14, 2026 · 09:05 ETCOMPANY'S OWN WORDS
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.…

BMRN +0.9% todayRead at source ↗
● PRNewsWireSep 9, 2026 · 09:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demo…

BMRN +0.9% todayRead at source ↗

Expected by Feb 23. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just BMRN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.